Navidea Biopharmaceuticals, Inc. (NAVB): Price and Financial Metrics
GET POWR RATINGS... FREE!
NAVB POWR Grades
- NAVB scores best on the Sentiment dimension, with a Sentiment rank ahead of 67.33% of US stocks.
- NAVB's strongest trending metric is Value; it's been moving up over the last 176 days.
- NAVB ranks lowest in Quality; there it ranks in the 10th percentile.
NAVB Stock Summary
- With a market capitalization of $38,641,268, Navidea Biopharmaceuticals Inc has a greater market value than just 6.25% of US stocks.
- With a price/sales ratio of 55.17, Navidea Biopharmaceuticals Inc has a higher such ratio than 95.59% of stocks in our set.
- With a year-over-year growth in debt of -63.13%, Navidea Biopharmaceuticals Inc's debt growth rate surpasses merely 6.37% of about US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to Navidea Biopharmaceuticals Inc are SCYX, MOSY, FLUX, UTSI, and EMAN.
- Visit NAVB's SEC page to see the company's official filings. To visit the company's web site, go to www.navidea.com.
NAVB Valuation Summary
- In comparison to the median Healthcare stock, NAVB's price/sales ratio is 1394.74% higher, now standing at 56.8.
- NAVB's price/earnings ratio has moved down 11.9 over the prior 243 months.
- NAVB's price/sales ratio has moved up 55.5 over the prior 243 months.
Below are key valuation metrics over time for NAVB.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| NAVB | 2021-08-31 | 56.8 | 8.7 | -4.1 | -3.8 |
| NAVB | 2021-08-30 | 56.8 | 8.7 | -4.1 | -3.8 |
| NAVB | 2021-08-27 | 56.1 | 8.6 | -4.1 | -3.7 |
| NAVB | 2021-08-26 | 55.0 | 8.4 | -4.0 | -3.6 |
| NAVB | 2021-08-25 | 54.0 | 8.3 | -3.9 | -3.6 |
| NAVB | 2021-08-24 | 56.1 | 8.6 | -4.1 | -3.7 |
NAVB Growth Metrics
- Its 2 year net cashflow from operations growth rate is now at 14.5%.
- Its year over year net cashflow from operations growth rate is now at -26.34%.
- The year over year revenue growth rate now stands at 14.24%.
The table below shows NAVB's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-06-30 | 0.872423 | -10.66532 | -11.9495 |
| 2021-03-31 | 0.882478 | -10.285 | -11.67886 |
| 2020-12-31 | 0.915013 | -8.173793 | -11.38558 |
| 2020-09-30 | 0.815061 | -8.350325 | -11.15377 |
| 2020-06-30 | 0.783483 | -8.062057 | -10.92298 |
| 2020-03-31 | 0.772474 | -8.140716 | -11.19276 |
NAVB Stock Price Chart Interactive Chart >
NAVB Price/Volume Stats
| Current price | $1.30 | 52-week high | $3.15 |
| Prev. close | $1.28 | 52-week low | $1.21 |
| Day low | $1.26 | Volume | 23,000 |
| Day high | $1.33 | Avg. volume | 177,668 |
| 50-day MA | $1.57 | Dividend yield | N/A |
| 200-day MA | $1.79 | Market Cap | 39.24M |
Navidea Biopharmaceuticals, Inc. (NAVB) Company Bio
Navidea Biopharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of precision radiopharmaceutical diagnostics for diseases such as cancer.
Latest NAVB News From Around the Web
Below are the latest news stories about Navidea Biopharmaceuticals Inc that investors may wish to consider to help them evaluate NAVB as an investment opportunity.
Navidea Biopharmaceuticals, Inc. (NAVB) Q3 2021 Results - Earnings Call TranscriptNavidea Biopharmaceuticals, Inc. (NAVB) Q3 2021 Earnings Conference Call November 10, 2021, 05:00 PM ET Company Participants Mike Rosol - Chief Medical Officer Erika Eves - Vice President of Finance and Administration Conference Call Participants Presentation Operator Greetings. Welcome to the Navidea Q3 2021 Earnings Conference Call. [Operator Instructions] Please... |
Navidea Biopharm EPS beats by $0.03Navidea Biopharm (NYSE:NAVB): Q3 GAAP EPS of -$0.08 beats by $0.03. Revenue of $0.97M (+259.3% Y/Y) Press Release... |
Will Navidea Biopharma (NAVB) Report Negative Q3 Earnings? What You Should KnowNavidea (NAVB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Navidea Biopharmaceuticals to Host Third Quarter 2021 Earnings Conference Call and Business UpdateDUBLIN, Ohio, November 03, 2021--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call and webcast on Wednesday, November 10, 2021 at 5:00 p.m. (EST) to discuss financial results and corporate developments for the third quarter ended September 30, 2021. |
Navidea Biopharmaceuticals Announces Resignation of Jed A. LatkinDUBLIN, Ohio, October 26, 2021--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the resignation of Jed A. Latkin as Chief Executive Officer, Chief Financial Officer and Chief Operating Officer of the Company, and as a member of the Board of Directors of the Company, effective October 24, 2021. Mr. Latkin and the Company are discussing the terms of |
NAVB Price Returns
| 1-mo | -13.91% |
| 3-mo | -20.73% |
| 6-mo | -26.14% |
| 1-year | -45.83% |
| 3-year | -65.79% |
| 5-year | -91.77% |
| YTD | -39.53% |
| 2020 | 70.63% |
| 2019 | -37.00% |
| 2018 | -72.22% |
| 2017 | -43.75% |
| 2016 | -51.88% |
Continue Researching NAVB
Here are a few links from around the web to help you further your research on Navidea Biopharmaceuticals Inc's stock as an investment opportunity:Navidea Biopharmaceuticals Inc (NAVB) Stock Price | Nasdaq
Navidea Biopharmaceuticals Inc (NAVB) Stock Quote, History and News - Yahoo Finance
Navidea Biopharmaceuticals Inc (NAVB) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...